INO stock forecast, quote, news & analysis
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases... Show more
Why Inovio Pharmaceuticals (INO) Stock Is Up +105% in the Last 30 Days
Key Takeaways
- INO shares climbed roughly 105% over the past 30 days, rising from about $0.66 to around $1.36.
- The rebound followed a sharp late-July selloff tied to a $20 million equity offering that diluted existing shareholders.
- Investor attention remains centered on the FDA decision for lead candidate INO-3107 in recurrent respiratory papillomatosis (RRP), with a PDUFA target action date of October 30, 2026.
- Second-quarter 2026 results showed a narrower net loss of $0.07 per share, and Jefferies upgraded the stock to Buy with a $3.00 price target.
- The stock remains highly volatile and well below its 52-week high, reflecting binary event risk ahead of the FDA decision.
Inovio Pharmaceuticals (INO) Company Overview and Market Position
Inovio Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to treat and protect people from HPV-related diseases, cancer, and infectious diseases. Its platform combines precisely designed DNA plasmids with a proprietary electroporation delivery device called CELLECTRA, which is intended to deliver genetic material into cells without viral vectors or lipid nanoparticles.
The company's lead program, INO-3107, is an investigational DNA immunotherapy for recurrent respiratory papillomatosis, a rare and chronic condition caused by HPV types 6 and 11. Inovio is also advancing VGX-3100 for HPV-related cervical dysplasia, which has been licensed to ApolloBio for Greater China, as well as next-generation DNA-encoded monoclonal antibody and DNA-encoded protein programs. With no approved commercial products yet, the stock is closely watched as a binary, event-driven bet on regulatory outcomes rather than current revenue.
Inovio Pharmaceuticals (INO) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, INO shares advanced approximately 105%, moving from a closing level near $0.66 to roughly $1.36. The gain was concentrated after a late-July trough, when the stock fell to an intraday low around $0.57 before reversing sharply higher through August.
The trailing three-month picture tells a more volatile story. The stock traded near $1.14 in early June and briefly reached the low $1.20s in early July before the late-July financing announcement pushed shares to multi-year lows. The subsequent recovery leaves the stock up roughly 19% over the trailing quarter on a net basis, though that headline figure understates the intra-period swings. The stock remains well below its 52-week high of approximately $2.98.
What Drove INO Stock Price in the Last 30 Days
The dominant catalyst was the unwind and recovery of a dilution-driven selloff. On July 29, 2026, Inovio announced a $20 million public offering priced at $0.95 per share, with attached warrants. The dilutive terms triggered a sharp decline that pushed shares to around $0.656 by July 30, marking the starting point for the subsequent rebound.
The recovery was driven by a series of positive updates. On August 12, Inovio reported second-quarter 2026 results showing a net loss of $6.0 million, or $0.07 per share, a substantial improvement from $23.5 million, or $0.61 per share, in the prior-year period. Management also disclosed that the FDA had completed its late-cycle review meeting and all scheduled pre-licensure inspections for INO-3107, keeping the program on track for its October 30, 2026 PDUFA date.
Analyst sentiment added momentum. On August 13, Jefferies upgraded Inovio from Hold to Buy and raised its price target to $3.00 from $1.80, citing progress in the FDA review process. H.C. Wainwright separately reiterated a Neutral rating with a $2.50 price target. Together, these catalysts helped fuel a multi-week rally in a small-cap stock with elevated short interest and high volatility.
What Drove INO Stock Performance Over the Last Quarter
The broader quarterly narrative centers on Inovio's transition toward a potential first commercial launch. The FDA accepted the Biologics License Application for INO-3107 under the accelerated approval pathway in December 2025, setting a PDUFA target action date of October 30, 2026. Throughout the quarter, the company completed key review milestones, including pre-licensure inspections and an informal clinical meeting with the agency.
Financing activity shaped the trading pattern. The July public offering generated approximately $18.3 million in net proceeds, extending the company's projected cash runway into late first quarter 2027 and through a potential launch. While the offering pressured the stock near term, it reduced near-term liquidity risk. Pipeline news also supported sentiment, including positive Phase 3 topline results for VGX-3100 reported by partner ApolloBio in China, which validated the DNA-medicine platform for HPV-related disease.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots. Tickeron operates hundreds of AI trading bots across thousands of tickers, but only the top-performing and most relevant bots appear in this featured section. Each bot differs in trading strategy, holding timeframe, and performance metrics, allowing users to compare approaches based on their own objectives and risk tolerance. For traders seeking an automated, data-driven way to monitor momentum across the market, exploring this section can offer a useful starting point for discovering strategies that align with current conditions.
INO Stock Forecast Drivers: What Investors Should Watch Next
The most significant upcoming catalyst is the FDA's decision on INO-3107, with a PDUFA target action date of October 30, 2026. Key items to monitor include the agency's view on accelerated approval eligibility, feedback on the confirmatory trial design, and the outcome of label negotiations, which management indicated could begin in September.
Investors should also track commercial readiness ahead of a potential launch, including the build-out of the sales organization through Syneos Health and competitive dynamics with the already-approved RRP therapy Papzimeos. Financial factors remain important as well: the company's cash runway extends into late first quarter 2027, but further capital-raising may be required depending on launch timing and spending. Broader pipeline progress, including a potential regulatory filing for VGX-3100 in China and partnership discussions for next-generation programs, represents additional longer-term drivers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
INO in upward trend: price rose above 50-day moving average on August 14, 2026
INO moved above its 50-day moving average on August 14, 2026 date and that indicates a change from a downward trend to an upward trend. In of 49 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 13, 2026. You may want to consider a long position or call options on INO as a result. In of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for INO just turned positive on August 13, 2026. Looking at past instances where INO's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for INO crossed bullishly above the 50-day moving average on August 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INO advanced for three days, in of 229 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 162 cases where INO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
INO broke above its upper Bollinger Band on August 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. INO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (32.154) is normal, around the industry mean (20.583). P/E Ratio (0.000) is within average values for comparable stocks, (27.923). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.559). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (443.835).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of synthetic vaccines and immune therapies for cancers and infectious diseases
Industry Biotechnology